OncoMatch/Clinical Trials/NCT06961955
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
Is NCT06961955 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: ESR1 estrogen receptor positivity less than 5%
Estrogen receptor positivity less than 5%
Disease stage
Excluded: Stage NODE POSITIVE, METASTASES
Breast cancer stage (AJCC v8) T0-3, N0, M0. T0 N0 is allowed if whole breast radiation is recommended by the treating physician.
Performance status
ECOG OR KPS 0–2
ECOG Performance Status ≤ 2, or KPS ≥ 50
Demographics
Prior therapy
Must have received: lumpectomy
Lumpectomy within 84 days of the start of radiation.
Cannot have received: radiation therapy to the chest
Prior radiation therapy to the chest.
Cannot have received: chemotherapy
Prior chemotherapy.
Cannot have received: prior breast malignancy
Prior breast malignancy in either breast.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute/University of Utah · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06961955 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages